Abstract:Background Stimulator of interferon genes (STING) is an innate immune sensor of cytoplasmic double-stranded DNA originating from microorganisms and host cells. The activation of cytosolic DNA-STING pathway in tumor microenvironments is usually linked to more robust adaptive immune responses to tumors, however the intracellular function of STING in regulatory T cells is largely unknown. In the present study, we aimed to explore the contribution of intracellular STING activation to regulatory T cell induction (iTreg) in cervical cancer (CC) microenvironments. Methods Blood samples and tumor specimens were obtained from patients with CC. The intratumoral STING, CCL22, CD8 and forkhead box P3 (FOXP3) expression levels were measured by immunohistochemistry. T cell-specific STING conditional knockout mice (CD4-Cre/STING(flox/flox), TKO) were generated, and syngeneic TC-1 tumor model were investigated. The differentiation and molecular regulatory pathway of human and murine iTreg under different treatments were investigated by ex vivo assays, immunoblotting and quantitative PCR. Tumor-associated exosomes (T-EXO) were isolated from CC cell lines and exosomal contents were identified by ELISA and Western blot analysis. The impact of T-EXO on T cell differentiation was tested in in vitro cell culture. Results Increased STING, CCL22 level, FOXP3(+) cells but decreased CD8(+) cells in tumor tissues predicted poor survival. Tumor-bearing CD4-Cre-STING(flox/flox) (TKO) mice displayed slower tumor growth tendencies as well as fewer FOXP3(+) cells but higher CD8(+) cell proportion in tumor tissues than wild-type (WT) mice. Activating of STING signaling cooperated with T cell receptor, interleukin-2 receptor and transforming growth factor-beta (TGF-beta) signals to promote CD4(+)CD25(high)FOXP3(+) iTreg differentiation from both human and murine CD4(+)-naive T cells from WT and IFNAR(-/-) mice but not TKO or IRF3(-/-) mice in vitro. Ectopic STING, TBK1 or IRF3 expression promoted iTreg differentiation from human CD4(+)-naive T cells. T cell-intrinsic STING activation induced FOXP3 transcription through TBK1-IRF3-mediated SMAD3 and STAT5 phosphorylation independent of interferon-beta. In CC, tumor-derived exosomes activated STING signaling in tumor-infiltrated T cells by exosomal TGF-beta, cyclic GMP-AMP synthase and 2'-3'-cGAMP, leading to iTreg expansion. Conclusions These findings highlight a novel mechanism for iTreg expansion mediated by tumor-derived exosome-activated T cell-intrinsic STING signal, and provide a rationale for developing immunotherapeutic strategies targeting STING signal in CC.

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake

DNA sensing via STING regulates autoimmunity and tumor immunity. (IRM5P.648)

Blocking Tim-3 Enhances the Anti-Tumor Immunity of STING Agonist ADU-S100 by Unleashing CD4+ T Cells Through Regulating Type 2 Conventional Dendritic Cells.

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

STING Promotes the Growth of Tumors Characterized by Low Antigenicity Via IDO Activation.

Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors

Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

Targeting STING oligomerization with small-molecule inhibitors

GAS-STING: a classical DNA recognition pathways to tumor therapy

Abstract LB114: STING licensing of type I dendritic cells potentiates antitumor immunity

KDM5 Histone Demethylases Repress Immune Response Via Suppression of STING

Tumor-Derived cGAMP Regulates Activation of the Vasculature

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells